Investor Event S E P T E M B E R 1 5,
|
|
- Delphia Boyd
- 5 years ago
- Views:
Transcription
1 Investor Event S E P T E M B E R 1 5,
2 Today s Presenters 10:00 10:45 a.m. 10:45 11:00 a.m. 11:00 11:20 a.m. 11:20 11:45 a.m. Welcome Scott Solomon Investor Relations Cynosure Overview and SculpSure Introduction Michael Davin Chairman and Chief Executive Officer SculpSure Marketing Strategy Doug Delaney Executive Vice President of Worldwide Sales Financial Overview Tim Baker President and Chief Financial Officer The Practical Perspective Dr. Bruce Katz Medical Director, JUVA Skin & Laser Center 11:45 a.m. Noon Break Noon 12:30 p.m. Demonstration of SculpSure Protocol Dr. Bruce Katz 12:30 12:55 p.m. General Question-and-Answer Session 12:55 1:00 p.m. 1:00 p.m. Lunch Wrap-up and Closing Remarks Michael Davin Chairman and Chief Executive Officer 2
3 Forward-looking Statements Any statements in this presentation about future expectations, plans and prospects for Cynosure, Inc., including Cynosure s intention to repurchase shares of its common stock from time to time under the share repurchase program, Cynosure s intention to broaden its reach through expanded indications and marketing programs, research and development projects, and Cynosure s active pipeline of potential acquisition opportunities, as well as other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the market price of Cynosure's stock prevailing from time to time, the nature of other investment opportunities presented to the Company from time to time, the Company's cash flows from operations, levels of demand for procedures performed with Cynosure products and for Cynosure products themselves, competition in the aesthetic laser industry, general business and economic conditions, effects of acquisitions that Cynosure has made or may make, Cynosure's ability to develop and commercialize new products, Cynosure's reliance on sole source suppliers, the inability to accurately predict the timing or outcome of regulatory decisions, and economic, market, technological and other factors discussed in Cynosure's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this presentation represent Cynosure's views as of the date of this presentation. Cynosure anticipates that subsequent events and developments will cause its views to change. However, although Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this presentation. 3
4 Michael Davin Chief Executive Officer 4
5 Agenda Cynosure at a Glance Market Opportunity Non-Invasive Body Contouring SculpSure Introduction and Technology Overview SculpSure Benefits 5
6 Cynosure at a Glance 6
7 Who We Are The Leader in Energy-based Aesthetic Solutions 26 Flagship Workstations; 12 Major Treatment Areas 840 Employees in 12 Countries Installed Base of >50,000 Systems 48% of Business from Existing Customers International Distributors in 120 Countries 32% Revenue CAGR from
8 Global Brand Presence 132 Countries Laser Product Revenue by Sales Channel (Quarter ended 6/30/15) 19% 81% Direct Sales Force Third-party Distributors 8 8
9 We Offer Unsurpassed Product Coverage Non-invasive fat reduction Body contouring Cellulite treatment Hair removal Vascular treatment Tattoo removal Skin revitalization Sweat gland ablation Nail fungus Pigmentation Acne scars Women s health Surgical applications 9
10 Revenue Growth ($ in millions) 32% CAGR $226.0 $ % Growth YoY $153.5 $72.8 $81.8 $110.6 $134.6 $ H'14 1H'15 10
11 Market Opportunity 11
12 Capitalizing on Positive Market Dynamics Consumers spending billions to restore, repair and refresh U.S. market for non-surgical cosmetic procedures totaled $5 billion in Non-invasive fat reduction was fastest-growing nonsurgical procedure in Worldwide, roughly 24 million non-surgical cosmetic procedures were performed in Physicians focusing on profitably expanding their practices Changing dynamics of U.S. healthcare system Market CAGR Market Segment North America Europe Asia Latin America Total Energy Based Devices 9.1% 5.8% 12.1% 11.2% 9.3% Skin Tightening and Body Shaping 14.2% 10.6% 16.6% 12.8% 13.6% 1 American Society for Aesthetic Plastic Surgery 2 Medical Insight, Inc. 3 International Study of Aesthetic Plastic Surgeons 12
13 Addressable Worldwide Market for Body Contouring More than 1.3 billion adults aged 18 and older were overweight (BMI 25-30) in % of global population 18 and older Increased BMI creates risks for lifethreatening diseases such as: High blood pressure Stroke Diabetes Certain cancers Non-invasive body contouring is the fastest-growing area of aesthetic medicine * Prevalence of overweight/obese adults aged 20 years and older by sex in different countries * Source: World Health Organization, ASAPS 13
14 U.S. Addressable Market Core Physicians ~20,000 core physicians Approximately 9% of the market is penetrated Source: Health Advances interviews and analysis; physician data from the Association of American Medical Colleges (AAMC) 14
15 U.S. Addressable Market Non-Core Physicians ~270,000 non-core physicians < 1% of the market is penetrated Source: Health Advances interviews and analysis; physician data from AAMC 15
16 Demonstrated Success in Both Core and Non-Core Markets Approximate % of CYNO revenue 40% 60% Non-core Core 16
17 SculpSure 17
18 Cynosure: First in Lipolysis 2006: First FDA cleared laser lipolysis system for use in a minimally invasive procedure for the removal of unwanted fat SmartLipo MultiPlexing 2010: Noninvasive fat reduction proposed, theoretical analysis and ex vivo tissue test TriPlex : Abdominal studies demonstrate safety and efficacy and favorable comparison with cryolipolysis; Results presented at ASLMS : Early prototype May 2015: FDA clearance for flanks July 2015: FDA clearance for abdomen W 12W 18W 20W 30W 46W 40W, 24W, 15W 1064nm, 1320nm, 1440nm Thousands of systems sold and millions of procedures performed : Clinical study for FDA clearance (more than 100 patients treated in multisite study for flanks and abdomen); FDA submission February 2015 September 2015: CE Mark approval for SculpSure 18
19 SculpSure Non-Invasive Body Contouring with the Speed of Light World s first and only FDA-cleared noninvasive lipolysis device to treat stubborn fat in just 25 minutes Versatility with 4 flat, non-suction cooling applicators Treat more than 1 area during a 25-minute session Well tolerated treatment Independent proprietary modulation to control the delivery of energy while optimizing treatment Contact sensing to ensure safe and effective energy delivery Simple, hands-free operation with remote connectivity Lower cost of ownership for physicians practices Treats all Skin Types I VI 19
20 Fact vs. Fiction Is the procedure well tolerated? Yes The scientific data demonstrate that the sensation experienced by SculpSure patients is comparable with cryolipolysis SculpSure requires no suction to achieve fat reduction SculpSure is a well tolerated procedure with patients reporting minimal post-treatment discomfort Proprietary independent energy modulation and contact cooling No anesthesia or medication necessary Zero downtime post-treatment 20
21 Fact vs. Fiction Is light-based treatment as safe as cryolipolysis for non-invasive fat reduction? Yes FDA-cleared for non-invasive lipolysis of the flanks and abdomen Favorable safety profile An average of 93% of subjects in SculpSure s two U.S. clinical studies reported being satisfied with their treatment Proprietary preset energy modulation optimizes safety and clinical outcome 21
22 Fact vs. Fiction Can a laser effectively reduce fat non-invasively? Yes Controlled heating within 42 o C to 47 o C has been clinically shown to destroy subcutaneous adipose tissues while sparing overlying and underlying tissues. Statistically significant reductions in fat were achieved in SculpSure s clinical studies Cynosure has been a leader in laser lipolysis technology for nearly 10 years 22
23 What Physicians Are Saying Any effective device has some sort of sensation associated with it. Descriptions thereof are highly subjective to the patient being treated. I have personally had both cryolipolysis and SculpSure treatments. Although different, each is unique both of which are certainly within the tolerable limits that one would consider an acceptable non surgical fat reduction treatment without any form of anesthesia. Barry DiBernardo, M.D. Medical Director, New Jersey Plastic Surgery 23
24 What Physicians Are Saying SculpSure patients experience a feeling of warmth which becomes more noticeable at the end of the ramp phase and is modest during the dwell phase. Thus there is no protracted discomfort No cycles have needed to be interrupted due to discomfort, or for any other reason, in any patients treated at my site. Lawrence S. Bass, M.D., F.A.C.S. Director, Bass Plastic Surgery PLLC 24
25 What Physicians Are Saying We have had a great experience with SculpSure, treatment times are very short for largest areas compared to other non-invasive fat reduction devices now on the market. Patients have tolerated treatments very well, with minimal discomfort and there is negligible discomfort after treatment. Highly effective treatment results without the risks of major pain episodes post-treatment. Robert A. Weiss, M.D., F.A.A.D., F.A.C.Ph Director, Maryland Laser, Skin & Vein Institute President of the ASLMS 25
26 What Physicians Are Saying I am impressed with the basic research conducted in order to develop the treatment algorithms and the body of clinical evidence collected to date. My patients are very accepting of the treatment experience which prompted them to ask to have multiple areas treated in a single session. I have a wide variety of technology available in my office for non-invasive body contouring, and SculpSure is the device my staff is requesting be used for their own treatments. David H. McDaniel, M.D., FAAD Director, Laser & Cosmetic Center of Virginia 26
27 Superior Performance, Minimal Time 1060 nm Wavelength Energy Advantages Minimal absorption in melanin Can be used with all skin types High affinity for adipose tissue Targeted adipose penetration depth Energy Efficiency Low Absorption in Dermis Penetration Depth Efficacy in Adipose Tissue 27
28 Reduced Time to Treat Controlled Hyperthermic Laser Treatment Induces adipocyte injury by raising adipose temperature to a range of 42 o C to 47 o C Independent proprietary modulated energy delivery No damage to surrounding tissue SculpSure has one recommended setting Advanced Contact Cooling technology for optimal patient comfort Shorter treatment time is particularly appealing to busy professionals ( lunchtime lipo ) Treatment Time: SculpSure vs. Competitor 25min. TREATMENT 28
29 Flexible and Versatile Template System SculpSure Treatment Areas Versatility Templates and applicator system with 4 individual Patented Applicators for Contouring (PACs) Treats areas up to 2 times larger than the competitor s most commonly used applicator Multiple attachment configurations to customize treatments SIDE VIEW Control Easy to use flat, non-suction applicator design Unique placement template system provides control to treat patients problem areas 29
30 Patented Applicator Technology to Sculpt and Define APPLICATOR CONTACT SENSING CONTACT COOLING Target Selective wavelength to target fat cells below the dermis DERMIS PROPRIETARY ENERGY MODULATION Disrupt Highly efficient wavelength for controlled energy delivery FAT CELLS Eliminate Over time, the body naturally eliminates the fat cells 30
31 Flank Template Configurations 31
32 Flank and Abdomen Treatment Contact Sensing 32
33 Abdomen Template Configurations 33
34 SculpSure Clinical Overview 5 ASLMS podium presentations Clinical investigators: Dr. John Decorato Dr. Bruce Katz, Dr. Larry Bass and Multisite trials 100s of patients have been treated Over 90% patient satisfaction rate 1 Comfortable, well-tolerated treatment comparable with leading competitor Minimal post-treatment discomfort *Clinical and Histological Evaluations of a 1060nm Laser Device for Non-Invasive Fat Reduction - John W. Decorato, MD., F A C S. Rafael Sierra, Ph.D., Bo Chen, Ph.D., Westford, MA, Katz B, Doherty S. A multicenter study of the safety and efficacy of a non-invasive 1060 nm diode laser for fat reduction of the flanks. Paper presented at: 2015 Annual American Society for Laser Medicine and Surgery Conference; April 22-26; Kissimmee, FL. 34
35 Photos courtesy of B. Katz, MD Flank Before 1 tx; 12 weeks post Weight Change: -1 lbs 35
36 Photos courtesy of B. Katz, MD 36
37 Photos courtesy of L. Bass, MD Abdomen Before 1 tx; 12 weeks post Weight Change: +1 lbs 37
38 Photos courtesy of L. Bass, MD 38
39 Photos courtesy of S. Doherty, MD Core Before 1 tx; 6 weeks post SculpSure 39
40 Photos courtesy of S. Doherty, MD 40
41 Shorter Treatment Time Benefits Practitioners and Patients Pricing Model will Help High-Volume Practices Enhance Profitability Flanks Cryolipolysis One 25-minute treatment Two 60-minute treatments Both flanks Total treatment time: 25 minutes Both flanks Total treatment time: 120 minutes 41
42 Shorter Treatment Time Benefits Practitioners and Patients Pricing Model will Help High-Volume Practices Enhance Profitability Abdomen Cryolipolysis Abdomen Total treatment time: 25 minutes Abdomen Total treatment time: 60 minutes 42
43 SculpSure Benefits SculpSure is differentiated on three significant dimensions, appealing to both physicians and patients Versatile Convenient Profitable Four universal applicators can be employed in various combinations and directions to treat a wide range of body types Can accommodate non pinchable fat patients not treatable by competitors 25-minute treatment time is not disruptive to patients daily routines and may enable higher conversion to treatment than with competitors Ideal for busy professionals Well tolerated Requires no suction Faster treatment time generates higher profit per hour per patient More patients due to versatility and convenience Source: Health Advances interviews and analysis 43
44 Doug Delaney Executive Vice President of Worldwide Sales 44
45 Agenda Market Position SculpSure Sales Force Distribution Strategy Marketing Launch Timeline 45
46 Market Position Energy or Mechanism of Action Infrared laser Cryolipolysis Ultrasound Treatment Time 25 minutes 60 minutes 45 minutes Hands-free Yes Yes No Number of treatments Average ~2 Average ~2 3 46
47 World-Class Support on a Local Basis New internal/external team will deliver turn-key support to grow the business Dedicated Internal Marketing Specialists Educate office staff with online training and support Expect to add 5 to 10 by 3/31/16 Dedicated Field Marketing Reps Develop marketing strategies and support promotions and events to drive existing patient base and practice growth (add 15 to 20 by 3/31/16) Dedicated Field Clinical Specialists Provide ongoing advanced training Expect to add 8 to10 by 3/31/16 Additional Sales Support Distribution Leverage existing Expect to add 20 to 25 by 3/31/16 Future Programs DTC outreach program Treatment diagnostics 47
48 Leveraging Existing Customer Base and Product Offerings Current customers account for 46-48% of new system placements KOLs and regional luminaries Significant installed base U.S. and OUS More than 10 years of laser lipolysis expertise through Smartlipo brand Broad product line creates opportunities for bundling 48
49 Marketing Launch Timeline Soft Launch 2H 2015 Full Launch 1H
50 Q3: Limited Pre-Launch Release to Key Sales Territories is Underway Marketing Materials: Sales Brochure Sell Sheets Product Presentation Video Soft Launch 2H 2015 Full Launch 1H
51 Q4: Expanded Collateral and Support Marketing Materials: Sales Tools Brochure Sell Sheets Product Presentation Treatment Videos Physician Support: Internal Marketing Specialist Support External Marketing & Clinical Field Support Enhanced Online Portal Social Media Campaign Personalized Microsite Soft Launch 2H 2015 Full Launch 1H
52 Q4: Trade Shows European Academy of Dermatology & Venereology EADV Launch October 8 11, Copenhagen American Society for Dermatologic Surgery ASDS - Workshop October 15 18, Chicago American Society of Plastic Surgeons ASPS - Special Event October 16 20, Boston Soft Launch 2H 2015 Full Launch 1H
53 Q4: International Launch CE Mark approval received Direct Cynosure offices in UK, France, Germany and Spain Ongoing focus on international registrations Soft Launch 2H 2015 Full Launch 1H
54 1H: Launch Timeline January / February Consumers: Launch PR Campaign Social Media Campaign Internal: National Sales Meeting Q March / April American Academy of Dermatology ASLMS Soft Launch 2H 2015 Full Launch 1H
55 Summary SculpSure launch underway Leveraging global infrastructure Dedicated clinical, marketing and sales support Expect strong uptake from current Cynosure customers worldwide Proven success in core and non-core markets 55
56 Tim Baker President and CFO 56
57 Agenda SculpSure Business Model & Margin Profile Anticipated Launch Expenses Intellectual Property 57
58 SculpSure Business Model System List Price $150,000 4 laser diode applicators Template kit (attachment frames, attachment belts) On-site installation Clinical in-service 12-month warranty covers the system and applicators Margin profile 60%+ Extended warranty expected to be lower than traditional product line 58
59 Proprietary Applicator Design APPLICATOR CONTACT SENSING CONTACT COOLING DERMIS PROPRIETARY ENERGY MODULATION FAT CELLS Contact sensing and cooling ensure safe and effective energy delivery 59
60 Frame Attachments (Templates) Provide Flexibility to Treat Multiple Anatomical Areas 60
61 SculpSure Business Model Consumables Patented Application for Contouring (PAC) Price to practitioner: Sold in PAC keys of 100 applicator uses $50/applicator use (Each PAC key = $5,000) PAC key Example: 4-template configuration is 4 applicator uses ($200) Promotional pricing of $3,500 per PAC key through year-end Margin profile greater than 80% PAC key packaging 61
62 Shorter Treatment Time Benefits Practitioners and Patients Pricing Model will Help High-Volume Practices Enhance Profitability Flanks Cryolipolysis $100 $100 $125 $125 Cost to physician: $200 Both flanks Total treatment time: 25 minutes Cost to physician: $250 Both flanks Total treatment time: 120 minutes (60 per side) 62
63 Shorter Treatment Time Benefits Practitioners and Patients Pricing Model will Help High-Volume Practices Enhance Profitability Abdomen Cryolipolysis $200 $275 Cost to practitioner: $200 Total treatment time: 25 minutes Cost to practitioner: $275 Total treatment time: 60 minutes 63
64 Expenses Related to SculpSure Launch ($ in thousands) Expenses Q Q Q Personnel $200 $1,000 $1,600 Marketing $1,000 $1,100 $2,300 Total $1,200 $2,100 $3,900 64
65 Total Sales and Marketing Expense as a Percent of Total Revenue 40% 38% 36% 34% 32% 34% 32% 35% 33% 32% 30% 30% 30% 28% 26% Q3'14 Q4'14 Q1'15 Q2'15 Q3'15(e) Q4'15(e) Q1'16(e) % for estimated periods shown at midpoint of expected range 65
66 Intellectual Property 9 issued U.S. patents; 3 pending Applicator Device and methods of treatment Fiber detection Energy modulation Hands-free treatment 66
67 Summary Significant opportunity to penetrate large and vastly underserved global market Strong IP position Favorable margin profile on both the system and consumables Recurring revenue stream through PACs 67
68 Dr. Bruce Katz Medical Director, JUVA Skin & Laser Center Clinical Professor of Dermatology, Icahn School of Medicine at Mount Sinai Director, Cosmetic Surgery and Laser Clinic, Mount Sinai Medical Center 68
69 Background Dermatologist, educator and clinical researcher Manhattan-based cosmetic surgery and laser surgery practice serves patients worldwide Over 30 years in practice Led clinical development of Smartlipo and was the first physician to introduce the device in the U.S. Clinical Professor of Dermatology at the Mount Sinai School of Medicine Published extensively in leading medical and scientific journals Led one of two U.S. clinical studies submitted as part of FDA 510(k) application for SculpSure 69
70 Agenda My Practice SculpSure Clinical Experience Before and After Images SculpSure Advantages 70
71 JUVA Skin & Laser Center Perform over 4,000 cosmetic procedures annually Background in non-invasive lipolysis (Liposonix, Ultrashape, SculpSure) Number of clinical studies conducted for non-invasive body contouring KYTHERA Biopharmaceuticals, Lithera/Neothetics 71
72 The Science of Using Laser Energy to Destroy Adipose Tissue Laser lipolysis is a widely recognized and clinically accepted modality of removing fatty tissue Clinical data demonstrates that laser exposure results in significant release of fat from adipocytes while nonadipocytes remain intact Reproducible results of thermal injury to adipocytes within the target temperature zone of 40ºC to 47ºC Before and after image of laser lipolysis patient 72
73 Clinical Evaluations of a 1060nm Laser Device for Non-Invasive Fat Reduction (ASLMS 2014) John W. Decorato, MD, FACS Study Design 16 subjects in total were treated on the abdomen prior to abdominoplasty 1060nm diode laser with contact cooling for skin protection was used to cause injury to adipose tissue by establishing a controlled hyperthermic temperature of C Evaluation A thermocouple needle was placed into the treatment area to measure tissue temp at interval depths Tissue histology (H&E stain) was obtained at multiple follow-up intervals from 1 week to 24 weeks 73
74 Clinical and Histological Evaluations of a 1060nm Laser Device for Non-Invasive Fat Reduction John W. Decorato, MD, FACS Results In vivo abdominal tissue tests showed hyperthermic temperature can be achieved and maintained in subcutaneous adipose tissue by a 1060 nm laser in conjunction with surface cooling A prolonged exposure of subcutaneous tissue at the hyperthermic temperature can cause adipocyte injury 3 Month Post Conclusion Laser treatment was safe and well tolerated. No skin damage was observed. No sign of significant changes in blood lipid or liver chemistry after treatment 74
75 Clinical Evaluations of a 1060nm Laser Device for Non-Invasive Fat Reduction as Compared to Cryolipolysis (ASLMS 2014) John W. Decorato, MD, FACS Study Design 6 subjects were treated in split flank study with either laser, cryolipolysis or no treatment control 3 Month Post Evaluation Measurements included ultrasound, MRI and blinded photo evaluation at 3 and 6 months post treatment 75
76 Clinical Evaluations of a 1060nm Laser Device for Non-Invasive Fat Reduction as compared to Cryolipolysis John W. Decorato, MD, FACS Results MRI 3 month post Tx 6 month post Tx Fat Volume Reduction Average Reduction 3 Month Post Laser Side Cryo Side Laser Side Cryo Side 24% (±9%) 22% (±13%) 21% (±10%) 19% (±9%) Conclusion Laser hyperthermic treatment is safe with only mild and transient side effects. Ultrasound, MRI, and photographic evaluations shows similar level of fat reduction (up to 25%) by laser hyperthermia as compared to cryolipolysis 76
77 Fat Thickness Demonstrated by MRI Up to 25% Reduction in Stubborn Fat Control Side Laser treatment Baseline 3 month post Tx 6 month post Tx Clinical and Histological Evaluations of a 1060nm Laser Device for Non-Invasive Fat Reduction - John W. Decorato, MD, FACS 77
78 Clinical Study: Non-Invasive 1060nm Diode Laser for Fat Reduction of the Flanks Bruce Katz, MD, Sean Doherty, MD Study Design 49 patients received laser treatment to one flank The other side served as a control Follow-up conducted at 6 and 12 weeks post treatment 3 Month Post Evaluation Ultrasound measurements of fat thickness were performed at baseline, 6 and 12 weeks post treatment High resolution photographs were taken at baseline and 12 weeks post treatment Subjects were asked to complete a satisfaction questionnaire 78
79 Clinical Study: Non-Invasive 1060nm Diode Laser for Fat Reduction of the Flanks Bruce Katz, MD, Sean Doherty, MD Baseline Results Blinded board certified dermatologists were able to identify the post treatment photograph 90.3% of the time Statistically significant reductions were achieved based on comparing treated and control sides at 6 and 12 weeks 96% of the subjects rated that they were satisfied Most common side effect was mild to moderate tenderness after treatment 3 Month Post Conclusion The non-invasive 1060nm diode laser used in this study was a successful and safe means of fat reduction of the flanks 79
80 Photos Courtesy of Bruce Katz, MD Clinical Study: Non-Invasive 1060nm Diode Laser for Fat Reduction of the Flanks Bruce Katz, MD, Sean Doherty, MD Baseline 3 Month Post 80
81 Clinical Study: Non-Invasive Fat Reduction of the Abdomen with a 1060nm Diode Laser Lawrence Bass, MD, Sean Doherty, MD Baseline Study Design 35 subjects received a single treatment session with multiple applicators of 1060nm laser on the abdomen for fat reduction Evaluation Ultrasound imaging 3 Month Post and high resolution 2D photography at baseline, 6 and 12 weeks post treatment Weight was recorded at baseline and at each follow up visit Patient satisfaction was recorded at 12 weeks Blinded evaluators were asked to choose the baseline photo from randomized pre and post treatment sets Fat thickness change was measured using ultrasound imaging at 6 and 12 weeks 81
82 Clinical Study: Non-Invasive Fat Reduction of the Abdomen with a 1060nm Diode Laser Lawrence Bass, MD, Sean Doherty, MD Baseline Results Reviewers were able to identify the post treatment photograph 95% of the time Statistically significant reductions were achieved based on comparing 6 and 12 weeks to baseline 91% of subjects were satisfied with the treatment results The most common side effect was mild to moderate tenderness after treatment 3 Month Post Conclusion The data demonstrates that 1060nm light based noninvasive body contouring is an efficacious modality Consistent reduction in the thickness of the subcutaneous fat layer was demonstrated based on ultrasound measurements and blinded photographic assessment 82
83 SculpSure s Simple, Fast Treatment Algorithm Step 1 Assess and Mark up to 4 treatment areas Step 2 Customizable Attachment System Configure attachment frames and secure with adjustable straps 4 flat non-suction applicators, treat with any combination Each applicator = 6x4cm (24cm2); 4 applicators = 96cm2 Step 3 Applicator Placement Place applicators securely in the frames Green lights on the applicator indicate contact between the applicator and the patient 83
84 SculpSure s Simple, Fast Treatment Algorithm Step 4 25 Minute Hands-Free Treatment Initial 4 minutes to achieve target temperature (42-47 ) to damage adipocyte cells; Next 21 minutes 1060nm energy is delivered via proprietary modulation for effective and well tolerated treatment Step 5 Post-treatment Remove applicators, frames and straps from patient Patient treatment is complete, no post treatment massage needed 84
85 Photos courtesy of B. Katz, MD Flank Before 1 tx; 12 weeks post SculpSure Weight Change: + 2 lbs 85
86 Photos courtesy of B. Katz, MD 86
87 Photos courtesy of B. Katz, MD Flank Before 1 tx; 12 weeks post SculpSure Weight Change: - 2 lbs 87
88 Photos courtesy of B. Katz, MD 88
89 Photos courtesy of S. Doherty, MD Flank Before 1 tx; 12 weeks post SculpSure Weight Change: lbs 89
90 Photos courtesy of S. Doherty, MD 90
91 Photos courtesy of. Bass, MD Abdomen Before 12 weeks post SculpSure Weight Change: +1.8 lbs 91
92 Photos courtesy of L. Bass, MD 92
93 Photos courtesy of L. Bass, MD Abdomen Before 1 tx; 12 weeks post SculpSure Weight Change: + 1 lbs 93
94 Photos courtesy of L. Bass, MD 94
95 Photos courtesy of S.Doherty MD Abdomen Before 1 tx; 12 weeks post SculpSure Weight Change: + 2 lbs 95
96 Photos courtesy of S. Doherty, MD 96
97 Photos courtesy of S. Doherty, MD Abdomen Before 1 tx; 12 weeks post Weight Change: -4.4 lbs 97
98 Photos courtesy of S. Doherty, MD 98
99 Summary SculpSure is a well-tolerated and highly effective treatment Patients get the benefits of non-invasive fat reduction with no downtime The universal 4-applicator system allows convenient treatment of multiple anatomical areas this is challenging for other systems SculpSure s 25-minute treatment is ideal for today s busy, time-crunched professionals women and men Shorter treatment time enhances my practice s ROI Hands-free treatment with remote connectivity SculpSure offers the lowest total cost of ownership of any non-invasive fat reduction treatment on the market Expect SculpSure s favorability to serve an entry-point for new aesthetic patients to seek other non-invasive cosmetic procedures 99
100 Demonstration 100
101 Q&A Session 101
102 Michael Davin Chief Executive Officer 102
103 SculpSure Milestones: Receive European CE Mark International registrations Expanded clearances for treatment areas Applications beyond non-invasive fat reduction Additional distribution channels 103
104 Key Messages for the Day Cynosure continues its 25 year history of technology innovation and product excellence with the world s first hyperthermic laser for non-invasive fat reduction Business model creates recurring revenue and income streams and opportunity for higher margins over time SculpSure platform provides aesthetic practitioners with a versatile, convenient system that will delight patients by delivering great results Cynosure s suite of body contouring products offers physicians the tools to grow their body contouring practice 104
105 Investor Event S E P T E M B E R 1 5,
A Smarter Way To Sculpt. Frequently Asked Questions
A Smarter Way To Sculpt Frequently Asked Questions Results/Efficacy Q: How long will the improvement in my appearance last? A: The treated fat cells are permanently destroyed and will not regenerate. SculpSure
More informationThe Art of Body Shaping
The Art of Body Shaping Body Shaping Fat Layer Reduction Selective Fat Cell Destruction Shape Your Success with UltraShape Power The Most Comfortable and Painless Fat Reduction Treatment UltraShape Power
More informationThe Art of Body Shaping
The Art of Body Shaping Body Shaping Fat Layer Reduction Selective Fat Cell Destruction Shape Your Success with UltraShape Power The Most Comfortable and Painless Fat Reduction Treatment UltraShape Power
More informationALLERGAN TO ACQUIRE ZELTIQ FOR $2.47B BEST-IN-CLASS COMPANY IN FAST GROWING BODY CONTOURING SEGMENT
ALLERGAN TO ACQUIRE ZELTIQ FOR $2.47B BEST-IN-CLASS COMPANY IN FAST GROWING BODY CONTOURING SEGMENT ALLERGAN CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Statements contained in this presentation
More informationPersonalized Body Sculpting: The Next Evolution
Personalized Body Sculpting: The Next Evolution Innovation Unlike Anything Else trusculpt id is the latest body sculpting technology giving you a personalized, hands-free and hand-held solution to revolutionize
More informationRumpa Linpiyawan, MD. Biography - Certified Board of Internal Medicine - Certified Board of Dermatology, Board of Family Medicine
Rumpa Linpiyawan, MD Biography - Certified Board of Internal Medicine - Certified Board of Dermatology, Board of Family Medicine Dr. Rumpa is a well-known dermatologist who had been assistant Professor
More information34 th Annual J.P. Morgan Healthcare Conference
JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains
More informationOBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss
OBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss Forward looking statements Except for statements of historical fact, information
More informationAesthetic Laser - Medical Devices Pipeline Assessment, 2016
Aesthetic Laser - Medical Devices Pipeline Assessment, 2016 Aesthetic Laser - Medical Devices Pipeline Assessment, 2016 BioPortfolio has been marketing business and market research reports from selected
More informationGolden standard for non-invasive body shaping Focused
U Ⅱ Golden standard for non-invasive body shaping Focused Focused pulsed ultrasound for selective fat cell destruction without downtime. U Ⅱ Golden standard for non-invasive body shaping U-Shape II uses
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More information7 Ways to Improve Your Liposuction Results. Karen Cronholm Product Manager April 21, 2011
7 Ways to Improve Your Liposuction Results Karen Cronholm Product Manager April 21, 2011 What value does Smartlipo TriPlex add to my practice? There are 7 Ways. Reason #1 Smartlipo s unique technology
More informationVelaShape II. Cellulite Treatment & Body Contouring. Science. Results.Trust.
VelaShape II Cellulite Treatment & Body Contouring Science. Results.Trust. "In my practice, word of mouth has spread fast and many of my patients are asking for VelaShape treatments. Patients who came
More informationForward-looking Statement Disclaimer
Forward-looking Statement Disclaimer This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to
More informationContour Your Body Quickly and Comfortably!
Body Contouring A Brand You Trust for Your Growing Aesthetic Center Contour Your Body Quickly and Comfortably! Syneron-Candela has developed a new line of products called Adeline, specifically designed
More informationJanuary 2017 Investor Presentation. confidently live life with ease
January 2017 Investor Presentation confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
More informationCorporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015
(Nasdaq:EVAR) Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015 Safe Harbor This presentation contains forward-looking statements as that term is defined in the Private Securities Litigation
More informationAESTHETIC TECHNOLOGIES. Proven Marketing and Aesthetic Technologies Designed to Maximize Your Earning Potential
AESTHETIC TECHNOLOGIES Proven Marketing and Aesthetic Technologies Designed to Maximize Your Earning Potential Tristar s Business System A Targeted Fat Loss & Skin Tightening Procedure that is painless,
More informationVisionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics
Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce
More information(Nasdaq: VIVE) Advancing the Science of Women s Intimate Health. December 2018
(Nasdaq: VIVE) Advancing the Science of Women s Intimate Health December 2018 Safe Harbor Statement All statements in this presentation that are not based on historical fact are forward looking statements.
More informationCorporate Presentation
Corporate Presentation January 2019 2018 Chembio. All Rights Reserved. # 2019 Chembio. All Rights Reserved. Page 1 Safe Harbor Statement Statements contained herein that are not historical facts are forward-looking
More informationconfidently live life with ease Management Presentation
confidently live life with ease Management Presentation 1 Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could cause
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationMyriad Genetics Corporate Presentation 06/13/2018
Myriad Genetics Corporate Presentation 06/13/2018 Copyright 2016 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Some of the information presented here today
More informationCLINICAL OVERVIEW. Clinical Studies Protocols Before & Afters
CLINICAL OVERVIEW Clinical Studies Protocols Before & Afters UltraShape Results 3 treatment regimen in use for 3 years Average circumference reduction ranges from 3.3 to 6.3 cm Average response rate ranged
More informationA G E N D A. I. Non-Invasive Body Contouring II. Benefits III. Treatment Options IV. Treatment Zones V. Q&A VI. Media VII.Results
A G E N D A I. Non-Invasive Body Contouring II. Benefits III. Treatment Options IV. Treatment Zones V. Q&A VI. Media VII.Results What is Non-Invasive Body Contouring? Don t want any incisions when contouring?
More informationAsia-Pacific Electrophysiology Market Outlook to 2020
Asia-Pacific Electrophysiology Market Outlook to 2020 Reference Code: GDMECR0114DB Publication Date: May 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 5 1.2 List of Figures...
More informationAwide range of technologies are available to perform esthetic
High-Intensity Focused Ultrasound Effectively Reduces Adipose Tissue Afschin Fatemi, MD Liposonix is considered to be a nonsurgical treatment for body contouring that uses high-intensity focused ultrasound
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationCompany Overview. Dr. Neal Walker President and CEO. September Copyright 2016 Aclaris Therapeutics. All rights reserved.
Company Overview Dr. Neal Walker President and CEO Copyright 2016 Aclaris Therapeutics. All rights reserved. A-11 Disclaimer This presentation contains forward-looking statements, including statements
More informationAnnual Shareholders Meeting
Annual Shareholders Meeting February 8, 2018 Dow R. Wilson, President and Chief Executive Officer Forward-Looking Statements Except for historical information, this presentation contains forward-looking
More informationYour SculpSure Treatment. Patient Consultation Guide
Your SculpSure Treatment Patient Consultation Guide The SculpSure Advantage Even with diet and exercise, stubborn fat seems impossible to lose. SculpSure s light-based body contouring technology targets
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationCell Therapy. Cytori Corporate Presentation January 2012
Cytori Corporate Presentation January 2012 Safe Harbor This presentation may contain certain forward-looking statements. All statements, other than statements of historical fact, that address activities,
More informationLEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017
LEERINK GLOBAL HEALTHCARE CONFERENCE Marino Garcia EVP, Chief Strategy Officer February 15, 2017 SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting
More informationSupplement to July/August 2015 CLINICAL CASE BOOK SELECTIVE RADIOFREQUENCY FAT REDUCTION IN PRACTICE
Supplement to July/August 2015 CLINICAL CASE BOOK SELECTIVE RADIOFREQUENCY FAT REDUCTION IN PRACTICE BEFORE AFTER 42-year-old woman with localized adiposity in abdominal and lateral flanks regions underwent
More informationFirst Albany Orthopedics Conference Marina Village, San Diego February 13, 2007 Orthofix International
First Albany Orthopedics Conference Marina Village, San Diego February 13, 2007 Orthofix International Tom Hein, CFO Safe Harbor Statement Except for historical information contained herein, the statements
More informationAsia-Pacific Bariatric Surgery Devices Market Outlook to 2020
Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020 Reference Code: GDMECR0195DB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List
More informationbody Reshape your body Renew your look Redefine you sculpting center Dramatic Aesthetic Results With a Spa-Like Feel
body sculpting center Connecticut Dermatology Group (CDG) is excited to announce the opening of the aesthetic Body Sculpting Center, an extension of their Norwalk office. Dramatic Aesthetic Results With
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationLIGHT SERIES MULTIPLE WAVELENGTHS FOR THE HIGHEST CHALLENGES IN LASER APPLICATIONS
LIGHT SERIES MULTIPLE WAVELENGTHS FOR THE HIGHEST CHALLENGES IN LASER APPLICATIONS ALEXANDRITE 755nm 1064nm 532nm 1320nm 1 TAKING CARE OF PEOPLE, OUR MASTERPIECES Quanta System was born in 1985 as a spin-off
More informationInnovative laser diode system for body shaping and fat reduction
The company Innovations Chromogenex have been at the forefront of laser and light based technology for over 20 years. Established in 1986 the company has grown from a manufacturing and repair service to
More informationUroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011
Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011 Forward Looking Statement This presentation includes forward-looking statements, including financial projections, relating
More informationBRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2020
BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook Reference Code: GDMECR0130PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...
More informationForward Looking Statements and Further Information
JANUARY 2015 [ 1 ] Forward Looking Statements and Further Information SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements. All statements other than
More informationNEW IN-DEMAND AESTHETICS IN ONE PLATFORM TECH BREAKTHROUGH PLUS
FRACTIONAL RESURFACING & REJUVENATION FACE & BODY REMODELING PLUS IPL SKIN REJUVENATION LASER HAIR REMOVAL - ULTIMATE SPEED NON-INVASIVE BODY CONTOURING & CELLULITE TREATMENT NEW TECH BREAKTHROUGH IN-DEMAND
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy DECEMBER 6, 2012 KJETIL HESTDAL, CEO Disclaimer The information included in this Presentation contains certain forward-looking statements that address activities, events
More informationSince both the demand for body contouring and interest in
November 2016 1402 Volume 15 Issue 11 Copyright 2016 ORIGINAL ARTICLES Journal of Drugs in Dermatology SPECIAL TOPIC Hands-Free Noninvasive Body Contouring Devices: Review of Effectiveness and Patient
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year
More informationAsia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures Outlook to 2020
Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Reference Code: GDMECR0107PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3
More informationSyneron Raises the Bar in Energy-Based Body Shaping
SYNERON SUPPLEMENT Syneron Raises the Bar in Energy-Based Body Shaping By Jeffrey Frentzen, Executive Editor For many years, Syneron, Ltd. (Yokneam, Israel), has been at the forefront of developing energy-based
More informationCorporate Presentation Fourth Quarter 2017
Corporate Presentation Fourth Quarter 2017 November 2017 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationSlide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationItamar Medical. December Investors Presentation.
Itamar Medical December 2017. Investors Presentation. Disclaimer Itamar Medical Ltd. (the "Company") is furnishing this presentation and any information given during this presentation, solely for the consideration
More informationShareholder Presentation Annual Meeting 2018
Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)
More informationCoolTouchCTEV. Endovenous 1320nm Laser Treatment for Varicose Veins
CoolTouchCTEV Endovenous 1320nm Laser Treatment for Varicose Veins 99% EFFICACY Science. Results. Trust. 99% efficacy rate short procedure time fewer risks and complications than vein stripping ideal outpatient
More informationInnovation In Ophthalmics
Innovation In Ophthalmics Ophthalmic Innovation Summit @ AAO 2018 October 25, 2018 Mark Iwicki Chairman & CEO, Kala Pharmaceuticals Disclaimers and Notices This presentation contains forward-looking statements
More informationChina Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020
China Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020 Reference Code: GDMECC0079DB Publication Date: March 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2
More information- Plans Commercial Launch of three dosing options for Excellagen in pre-filled syringes
Generex Biotechnology Subsidiary Olaregen Therapeutix Inc. Plans Launch of FDA Cleared Excellagen Wound Conforming Gel Matrix with Three Dosage Options - Plans Commercial Launch of three dosing options
More informationDARA Reports Year-End 2012 Financial Results
April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,
More informationPatrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation
Patrick J. Sullivan Chief Executive Officer January 9, 2018 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationEU5 Bariatric Surgery Procedures Outlook to 2020
EU5 Bariatric Surgery Procedures Outlook to 2020 Reference Code: GDMECR0089PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...
More informationA GLOBAL LEADER IN PERSONALIZED NUTRITION
A GLOBAL LEADER IN PERSONALIZED NUTRITION Forward Looking Statements Management will make forward-looking statements during this presentation. Actual results could differ from those projected in such forward-looking
More informationAn In-Depth Examination of Radiofrequency Assisted Liposuction (RFAL)
An In-Depth Examination of Radiofrequency Assisted Liposuction (RFAL) by Dr R Stephen Mulholland MD, FRCS(C) Plastic Surgeon Toronto, Canada and Los Angeles, CA introduction There are a myriad of liposuction
More informationNeovasc Inc. Alexei Marko, CEO. January 2012 OneMedForum
Neovasc Inc. Alexei Marko, CEO January 2012 OneMedForum 2 Forward-Looking Statements Statements contained herein that are not based on historical or current fact, including without limitation statements
More informationFinancial Presentation
Financial Presentation Certain of the statements that will be made during this meeting, as well as statements contained in our 2006 Annual Report to Shareholders and Annual Report on Form 10-K filed with
More informationFor personal use only. Investor Briefing. Bayswater, 1 st December 2016
Investor Briefing Bayswater, 1 st December 2016 Introduction Samantha Cheetham Chief Executive Officer To be an innovative leader in the dental industry, developing our people and partnering with dentists
More informationProFractional. ProFractional Therapy. Tunable Fractional Solution. Advanced Fractional Aesthetic Laser Surgery
ProFractional-XC ProFractional ProFractional Therapy Tunable Fractional Solution Advanced Fractional Aesthetic Laser Surgery ProFractional-XC is taking fractionated resurfacing to the next level. Todd
More informationMexico Ostomy Drainage Bags Market Outlook to 2020
Mexico Ostomy Drainage Bags Market Outlook to 2020 Reference Code: GDMECC0990DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List of Figures...
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationBuilding a Global Neurotoxin Franchise
JUNE 2, 2014 Building a Global Neurotoxin Franchise DAN BROWNE President & CEO Forward-Looking Statements This presentation contains forward-looking statements, including statements related to the process
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationASX Investor Presentation
ASX Investor Presentation Sydney, Australia Dr Peter Neustadt Executive Chairman and CEO November 2014 Copyright and registered trademark notice ASX Investor Presentation Page 0 Who we are SomnoMed Limited
More informationSPECIAL TOPIC. Cosmetic Dermatology Center, McLean, VA b. Art of Skin, MD, Solana Beach, CA c. Dermatology Associates, Seattle, WA
December 2016 1557 Volume 15 Issue 12 Copyright 2016 ORIGINAL ARTICLES Journal of Drugs in Dermatology SPECIAL TOPIC A Clinical Evaluation of a Next Generation, Non-Invasive, Selective Radiofrequency,
More informationThe Professional Choice
The Professional Choice bout FormaTK Systems is a global developer and manufacturer of technologically driven and market oriented devices for the medical aesthetic market. Founded in 2008 by a group of
More informationdiva is a breakthrough laser resurfacing procedure for the improvement of internal vaginal tissue.
FOR VAGINAL HEALTH diva is a breakthrough laser resurfacing procedure for the improvement of internal vaginal tissue. divatyte is an external treatment for vaginal skin sciton.com/diva Invest in the rapidly
More informationImpact of the Current Economy on Facial Aesthetic Surgery
Facial Surgery Impact of the Current Economy on Facial Aesthetic Surgery Aesthetic Surgery Journal 31(7) 770 774 2011 The American Society for Aesthetic Plastic Surgery, Inc. Reprints and permission: http://www.sagepub.com/
More informationSPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator
More informationDelivering Results POSITIONED FOR GROWTH. Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental
Delivering Results POSITIONED FOR GROWTH Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental PAUL GUGGENHEIM CEO, Patterson Dental Former owner and president, Guggenheim Brothers
More informationOventus: Innovators in Sleep Apnoea Treatment Investor lunch presentation Tattersall s Club, Brisbane
Oventus: Innovators in Sleep Apnoea Treatment Investor lunch presentation Tattersall s Club, Brisbane February 2018 Twitter: @OventusLtd About Oventus (ASX: OVN) Oventus is commercialising its Airway Technology
More informationNASDAQ: ELGX December Innovation that Empowers
NASDAQ: ELGX www.endologix.com December 2014 Innovation that Empowers Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationUniversal Biosensors, Inc.
Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended
More informationSolutions For The Aging Spine
Solutions For The Aging Spine NASDAQ: ATEC February 2009 www.alphatecspine.com Slide 0 5818 El Camino Real, Carlsbad, CA 92008 www.alphatecspine.com Forward Looking Statements This presentation and our
More informationBackground Head Quarter Promoter Holding Pattern Turnover
PhotoMedex, Inc INTRODUCTION Background PhotoMedex is a global skin health medical technology company, providing integrated disease management and aesthetic solutions through complementary laser and light-based
More informationFood & Beverages Food for a growing world
Food & Beverages Food for a growing world Rasmus von Gottberg, Vice President F&B Marketing, Novozymes Christel Thea Jørgensen, Vice President R&D, Novozymes Jeremy Bentham, Go to Market Director, Cargill
More informationValneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth
Valneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth Strong sales performance in 2017 (unaudited) Total revenues of 109.8 million in 2017 (2016-97.9 million) representing year-on-year
More informationMAKO Surgical Corp. January MAKO Surgical Corp
MAKO Surgical Corp. January 2012 MAKO Surgical Corp. 2012 1 Forward Looking Statement This presentation contains forward-looking statements regarding, among other things, statements related to expectations,
More informationBetter Diagnostics for Life
NASDAQ: NMRD Better Diagnostics for Life Corporate Presentation November 2018 Forward-Looking Statement This presentation includes forward-looking statements that are subject to many risks and uncertainties.
More informationNoninvasive Modalities in Lipolysis. Michelle W. Foley, DO, FAOCD, FAAD
Noninvasive Modalities in Lipolysis Michelle W. Foley, DO, FAOCD, FAAD Disclosure Relevant Financial Relationship: Compensated speaker for Syneron Candela Lecture Objectives Introduction and overview of
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationUltraPulse Encore. Bridge Therapy Fractional CO 2.
UltraPulse Encore Bridge Therapy Fractional CO 2 www.aesthetic.lumenis.com bridging the gap BRIDGE THERAPY Bridge Therapy is the family of fractional treatments encompassing PigmentFX, ActiveFX, DeepFX
More informationIcon specifications. Handpiece compatibility
Icon specifications Voltage Frequency Max. power Speed Weight 90-264 VAC 50-60 Hz 1600 VA Up to 3 Hz (pulse rate) 104 lb. (47.1kg) Handpiece compatibility Handpiece Technologies Hair removal Pigmented
More informationINVESTOR MEETING ASTRO 2013
INVESTOR MEETING ASTRO 2013 Webcast will begin 7:15 a.m. EDT SEPTEMBER 24, 2013 2013 VARIAN MEDICAL SYSTEMS. ALL RIGHTS RESERVED. Forward-Looking Statements Except for historical information, this news
More informationMemory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia. -Broadens Roche Nicotinic Alpha-7 Alliance-
Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia -Broadens Roche Nicotinic Alpha-7 Alliance- -Secures Additional $5M Debt Financing to Support Phase 2a Trial-
More information